Ex-trader loses bid to dismiss insider trading case
Sean Stewart, a former executive with JP Morgan and Perella Weinberg Partners who is accused of insider trading based on his work on several medical device transactions, lost his bid to have criminal...
View ArticleINC Research taps new CFO | Personnel moves
INC Research Inc. hired a new CFO as the North Carolina-based clinical research organization charts course to make itself one of the biggest players in the CRO industry. David Gill has been CFO at...
View ArticleCRO merger: INC Research to buy Kendle for $232 million | Acquisitions roundup
Cincinnati-based contract research organization Kendle International Inc. (NSDQ:KNDL) has solved its “acquire-or-be-acquired” dilemma. Kendle agreed to sell itself to Raleigh, N.C.-based CRO INC...
View ArticleINC Research buys Australian CRO Trident to boost global presence
INC Research, still completing its $232 million acquisition of clinical research organization Kendle International Inc. (NSDQ:KNDL), bought yet another CRO to add to its global footprint. Raleigh, N....
View ArticleINC Research: No acquisitions in near future but CEO says ‘never say never’
INC Research’s Kendle acquisition vaulted the North Carolina clinical research organization into the CRO industry’s top five and, according to CEO James Ogle, helped the company become a global...
View ArticleHeartWare closes enrollment in destination therapy trial for heart pump |...
HeartWare International (NSDQ:HTWR) completed enrollment in a 450-patient pivotal trial considering its ventricular assist system as a destination therapy for patients with advanced heart failure. The...
View ArticleFeds charge ex-JP Morgan exec, father in medtech insider trading scheme
Federal prosecutors in New York this week charged a father-and-son team with insider trading connected with a spate of mergers in the medical device arena. Sean Stewart, a former executive with JP...
View ArticleConMed ripe for M&A | The week in medtech M&A
Analyst: ConMed ripe for M&A spree May 19, 2015 by Fink Densford ConMed, in the middle of an under-appreciated turnaround, could be poised to augment its growth via selective acquisitions,...
View Article
More Pages to Explore .....